Anticholinergic use is associated with lower mortality but not increased hip fracture risk in Parkinson's disease patients: a retrospective cohort study.

Po-Yen Ko, Po-Ting Wu, I-Ming Jou, Renin Chang, Ching-Hou Ma

Abstract read

In one paragraph

Article in BMC geriatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Po-Yen KoDepartment of Orthopedics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Po-Ting WuDepartment of Orthopedics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

I-Ming JouDepartments of Orthopedics , E-Da Hospital, Kaohsiung, Taiwan.

Renin Chang *Department of Emergency Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. rhapsody1881@gmail.com.

Ching-Hou Ma *Departments of Orthopedics , E-Da Hospital, Kaohsiung, Taiwan. ed100771@edah.org.tw.

Funding

E-Da Hospital, Kaohsiung, Taiwan. EDAHS110007

6 · The paper itself

Abstract

backgroundIt is unclear whether antiparkinsonism anticholinergics (AAs) increase hip fracture (HFx) risk in Parkinson's disease (PD) patients. This study examined associations between AAs, HFx and mortality in PD using Taiwan's National Health Insurance Database.

methodsNewly diagnosed PD patients ≥ 50yrs were categorized by AAs exposure: PD with AAs (≥ 90 days, n = 16,921), PD without AAs (never-exposed, n = 55,940), and demographically matched non-PD controls (n = 291,444). Competing risk of death was considered in Fine & Gray models analyzing HFx. Mortality was compared using Cox regression models.

resultsBoth PD groups were associated with higher HFx risk compared to non-PD controls (adjusted hazard ratio [HR] = 1.51 for PD with AAs; 1.53 without). No significant difference in HFx risk was observed between PD groups with and without AAs exposure. Both groups were associated with increased mortality compared to non-PD (adjusted HR = 2.24 with AAs; 2.44 without AAs). Among PD patients, those with AAs exposure were associated with lower mortality compared to those without AAs (adjusted HR = 0.93).

conclusionsPD was associated with increased HFx and mortality compared to non-PD, regardless of AAs exposure. AAs use was not associated with increased HFx risk and was associated with lower mortality. AAs use was not associated with increased fracture risk and was associated with lower mortality in PD, however further studies are needed to clarify these associations.

Indexed as

Cholinergic AntagonistsHip FracturesParkinson DiseaseAgedAged, 80 and overAntiparkinson AgentsCohort StudiesFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsTaiwanAntiparkinson AgentsCholinergic AntagonistsAntiparkisonism anticholinergic agentCohort studyHip fractureParkinson’s diseaseSurvival rate

Identifiers

PMID39558282

DOI10.1186/s12877-024-05535-8

PMCPMC11571509

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.